GSK-backed Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.
US-based immunotherapeutics developer Atreca has raised approximately $125m in an initial public offering that achieved an exit for pharmaceutical firm GlaxoSmithKline (GSK).
The offering consisted of 7.35 million class A shares on the Nasdaq Global Select Market priced at $17.00 each, in the middle of the IPO’s range. The underwriters have a 30-day option to buy 1.1 million extra shares to boost the offering to $144m.
Atreca is developing antibody-based immunotherapeutics to treat solid tumours, and $45m of the…
